Candriam SCA’s Praxis Precision Medicines PRAX Stock Holding History

Candriam SCA’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.4M	Sell	60,856 -2,772	-4%	-$878K	0.09%	200
2026 Q1	$20.5M	Sell	63,628 -46,962	-42%	-$14.5M	0.11%	192
2025 Q4	$32.6M	Buy	110,590 +47,724	+76%	+$8.89M	0.16%	136
2025 Q3	$3.33M	Sell	62,866 -805	-1%	-$39K	0.02%	416
2025 Q2	$2.68M	Hold	63,671	–	–	0.02%	450
2025 Q1	$2.41M	Sell	63,671 -54,299	-46%	-$3.39M	0.02%	458
2024 Q4	$9.08M	Sell	117,970 -44,061	-27%	-$3.19M	0.05%	275
2024 Q3	$9.32M	Buy	+162,031	New	+$8.75M	0.05%	280

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Candriam SCA's PRAX Position: Q2 2026 in Review

Candriam SCA reduced its Praxis Precision Medicines (PRAX) stake by 4.4% in Q2 2026, selling an estimated $878K and leaving 60,856 shares worth $20.4M. The position accounts for 0.09% of the portfolio, ranked #200.

Candriam SCA first reported a position in PRAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $32.6M in Q4 2025. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Candriam SCA held 60,856 shares of Praxis Precision Medicines worth $20.4M as of Q2 2026.
Candriam SCA sold 2,772 Praxis Precision Medicines shares in Q2 2026, an estimated $878K.
Praxis Precision Medicines made up 0.09% of Candriam SCA's portfolio in Q2 2026, its #200 holding.
Candriam SCA first reported a position in Praxis Precision Medicines in Q3 2024 and has held it in 8 quarters since.
Candriam SCA's Praxis Precision Medicines position peaked at $32.6M in Q4 2025.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.